🟢 Iovance Biotherapeutics is trading 4.36% up today after lifting 2026 revenue guidance

Iovance Biotherapeutics is trading at $15.08, up 4.36%, extending its September 29 rally after lifting 2026 revenue guidance.

• Guidance is now $410–$420 million, up from $350–$370 million, citing strong U.S. demand for Amtagvi and Proleukin; the midpoint increase is $55 million.
• The outlook upgrade is the clearest catalyst. Broader markets were also firmer, with the Nasdaq up 1.06% per the supplied market context.
• Available sources do not establish a separate September 30 announcement.